A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

被引：0
|
作者：
Smare, C. [1 ]
Dave, K. [1 ]
Juarez-Garcia, A. [2 ]
Schoenherr, N. [2 ]
Abraham, P. [3 ]
Penrod, J. R. [3 ]
Camidge, D. R. [4 ]
Yuan, Y. [3 ]
机构：
[1] PAREXEL Int, London, England
[2] Bristol Myers Squibb Pharmaceut Ltd, London, England
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Univ Colorado Denver, Aurora, CO USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN236
引用
收藏
页码：S481 / S481
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer
    Smare, Caitlin
    Dave, Kiran
    Juarez-Garcia, Ariadna
    Abraham, Pranav
    Penrod, John R.
    Camidge, D. Ross
    Yuan, Yong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1124 - 1133
  • [2] A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER
    Smare, C.
    Dave, K.
    Juarez-Garcia, A.
    Schoenherr, N.
    Abraham, P.
    Penrod, J. R.
    Camidge, D. R.
    Yuan, Y.
    [J]. VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [3] Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China
    Fei, Zhengyang
    Rui, Mingjun
    Wang, Yingcheng
    Ma, Aixia
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (01) : 79 - 87
  • [4] Cost-effectiveness analysis of nivolumab and apatinib in third-line gastric cancer therapy.
    Yuan, Jiajia
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
    Zhou, Dongchu
    Luo, Xia
    Zhou, Zhen
    Zeng, Xiaohui
    Wan, Xiaomin
    Tan, Chongqing
    Liu, Qiao
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [7] Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
    Zhu, Qiuyan
    Ni, Ronghua
    Guan, Xin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (08) : 1782 - 1789
  • [8] COST-EFFECTIVENESS ANALYSIS OF ANLOTINIB AS A THIRD-LINE OR FURTHER TREATMENT IN ADVANCED NON-SMALL LUNG CANCER
    Huang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S48 - S48
  • [9] Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer
    Keeping, Sam T.
    Cope, Shannon
    Chan, Keith
    Wilson, Florence R.
    Jansen, Jeroen P.
    Penrod, John R.
    Abraham, Pranav
    Camidge, D. Ross
    Korytowsky, Beata
    Gu, Tao
    Garcia, Ariadna Juarez
    Le, Trong K.
    Yuan, Yong
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (18) : 1275 - 1284
  • [10] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA
    Kim, Y. G.
    Lee, E. K.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A514 - A514
12345